Skip to main content

Table 1 Characteristics of all men enrolled at Wave 1, men not at risk and at risk for prostate cancer at Wave 2 or Wave 3 based on Wave 1 screen results, and at-risk men with incomplete and complete follow-up.

From: A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago

    Risk status after Wave 1 Follow-up  
  All Not at risk At risk Incomplete Complete  
  n = 3264 n = 717 n = 2547 n = 756 n = 1791  
Characteristic n1 % n1 % n1 % n1 % n1 % p-value2
Demographic            
   Age (years)            <.0001
40-44 624 19.1 59 8.2 565 22.2 151 20.0 414 23.1  
45-49 571 17.5 71 9.9 500 19.6 115 15.2 385 21.5  
50-59 914 28.0 166 23.2 748 29.4 221 29.2 527 29.4  
60-81 1155 35.4 421 58.7 734 28.8 269 35.6 465 26.0  
   Education (23)   (7)   (16)   (7)   (9)   0.76
≤11 years 2411 74.4 553 77.9 1858 73.4 553 73.8 1305 73.2  
12+ years 830 25.6 157 22.1 673 26.6 196 26.2 477 26.8  
   Marital status (26)   (10)   (16)   (7)   (9)   0.13
ever married 2669 82.4 590 83.5 2079 82.1 602 80.4 1477 82.9  
never married 569 17.6 117 16.5 452 17.9 147 19.6 305 17.1  
Family history of ...            
   Prostate cancer            0.02
missing 323 9.9 77 10.7 246 9.7 86 11.4 160 8.9  
yes 218 6.7 40 5.6 178 7.0 64 8.5 114 6.4  
no 2723 83.4 600 83.7 2123 83.4 606 80.2 1517 84.7  
History of ...            
   Smoking (21)   (7)   (14)   (3)   (11)   <.0001
yes 1410 43.5 341 48.0 1069 42.2 365 48.5 704 39.6  
no 1833 56.5 369 52.0 1464 57.8 388 51.5 1076 60.4  
   Cancer (43)   (13)   (30)   (9)   (21)   0.002
yes 26 0.8 11 1.6 15 0.6 10 1.3 5 0.3  
no 3195 99.2 693 98.4 2502 99.4 737 98.7 1765 99.7  
   Benign prostatic hypertrophy (84)   (24)   (60)   (17)   (43)   0.67
yes 248 7.8 78 11.3 170 6.8 53 7.2 117 6.7  
no 2932 92.2 615 88.7 2317 93.2 686 92.8 1631 93.3  
Entry prostate cancer screen            
   PSA (ng/mL) (190)   (190)         <.0001
0.0-0.9 1213 39.5 43 8.2 1170 45.9 306 40.5 864 48.2  
1.0-1.9 850 27.7 45 8.5 805 31.6 206 27.2 599 33.4  
2.0-2.9 268 8.7 21 4.0 247 9.7 84 11.1 163 9.1  
3.0-3.9 150 4.9 26 4.9 124 4.9 58 7.7 66 3.7  
4.0-9.9 354 11.5 199 37.8 155 6.1 73 9.7 82 4.6  
10+ 239 7.8 193 36.6 46 1.8 29 3.8 17 0.9  
   DRE            <.0001
missing 555 17.0 220 30.7 335 13.2 151 20.0 184 10.3  
positive 636 19.5 279 38.9 357 14.0 116 15.3 241 13.5  
negative 2073 63.5 218 30.4 1855 72.8 489 64.7 1366 76.3  
  1. PSA - prostate-specific antigen, DRE - digital rectal examination
  2. 1. Numbers in parentheses indicate missing data
  3. 2. Statistical significance (chi-square) of differences between at-risk men with incomplete and complete follow-up